Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Seizure ; 120: 173-179, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-39029407

RESUMEN

PURPOSE: To investigate the treatment of infantile epileptic spasm syndrome (IESS) in Denmark. METHODS: National retrospective cohort study of all patients born 1996-2019 who had a diagnosis of IESS in the National Patient Registry. Medical records were reviewed to evaluate the diagnosis. Patients were included if semiology was compatible with IESS, or if unclear semiology if there was an abnormal EEG or EEG with hypsarrhythmia. RESULTS: Number of cases with a register based IESS diagnosis was 538. Medical records were unavailable in 48 and 164 did not fulfil the inclusion criteria. Thereby the cohort consisted of 326 children. Mean age at onset of IESS was 5.9 months and mean lead time to treatment was 26.6 days (SD= 63.5). Consistent with the Danish treatment guidelines most patients received vigabatrin as first treatment. In the cohort 44.7 % of patients solely received vigabatrin, whereas combined vigabatrin and corticosteroid was given to 28.3 % (either hydrocortisone or prednisolone). Other anti-seizure medication was given to 28.4 % within 90 days of IESS onset. Aetiology was prenatal (40.3 %), perinatal (10.5 %), postnatal (3.7 %), with unknown timing (10.2 %) or with unknown aetiology (33.5 %). The cohort was followed to a mean age of 8.2 years. At latest follow-up severe neurodevelopmental outcome was seen in 44.2 % and 76.4 % still had epilepsy. The incidence of IESS was 22 per 100.000 live births. CONCLUSION: In Denmark treatment algorithm is based on start of treatment with vigabatrin. A total of 44.7 % became seizure free by vigabatrin. Neurodevelopmental outcome was severe. A national incidence could be established.


Asunto(s)
Anticonvulsivantes , Espasmos Infantiles , Vigabatrin , Humanos , Dinamarca/epidemiología , Espasmos Infantiles/epidemiología , Espasmos Infantiles/tratamiento farmacológico , Espasmos Infantiles/diagnóstico , Anticonvulsivantes/uso terapéutico , Lactante , Femenino , Masculino , Estudios Retrospectivos , Vigabatrin/uso terapéutico , Electroencefalografía , Sistema de Registros , Recién Nacido , Preescolar , Resultado del Tratamiento
2.
Acta Paediatr ; 112(3): 543-549, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-36435986

RESUMEN

AIM: Acute pyelonephritis is one of the most common bacterial infections in childhood. This potentially serious condition can lead to renal scarring, loss of kidney function and hypertension. The aim of this study was to identify risk factors associated with pyelonephritis in children without kidney or urinary tract abnormalities. METHODS: Medical records of children aged 4-18 diagnosed with 1st time pyelonephritis from 2016 to 2021 were retrospectively analysed. Children with abnormal kidney ultrasound were excluded. In addition to demographic data, information on bladder and bowel function was extracted together with habits of fluid intake. RESULTS: A total of 105 patients were diagnosed with 1st time pyelonephritis. Of these, 47% were diagnosed with constipation according to the Rome IV criteria within a mean follow-up period of 167 days after their pyelonephritis, which is markedly higher than the estimated prevalence of constipation in the background population. Constipation was positively associated with recurrent urinary tract infection (p = 0.01). CONCLUSION: Constipation is associated with pyelonephritis and recurrent urinary tract infection in children (primarily girls) 4-18 years of age without evident kidney or urinary tract abnormalities. We recommend systematic evaluation of bowel and bladder function after 1st time pyelonephritis in all children >4 years.


Asunto(s)
Pielonefritis , Infecciones Urinarias , Femenino , Humanos , Niño , Preescolar , Adolescente , Estudios Retrospectivos , Pielonefritis/complicaciones , Pielonefritis/epidemiología , Infecciones Urinarias/complicaciones , Infecciones Urinarias/epidemiología , Estreñimiento/etiología , Estreñimiento/complicaciones , Factores de Riesgo , Cicatriz/complicaciones
3.
Cardiol Young ; 27(1): 90-100, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27087410

RESUMEN

BACKGROUND: Right heart function is an important predictor of morbidity and mortality in pulmonary arterial hypertension and many CHD. We investigated whether treatment with the prostacyclin analogue treprostinil could prevent pressure overload-induced right ventricular hypertrophy and failure. METHODS: Male Wistar rats were randomised to severe pulmonary trunk banding with a 0.5-mm banding clip (n=41), moderate pulmonary trunk banding with a 0.6-mm banding clip (n=36), or sham procedure (n=10). The banded rats were randomised to 6 weeks of treatment with a moderate dose of treprostinil (300 ng/kg/minute), a high dose of treprostinil (900 ng/kg/minute), or vehicle. RESULTS: Pulmonary trunk banding effectively induced hypertrophy, dilatation, and decreased right ventricular function. The severely banded animals presented with decompensated heart failure with extracardial manifestations. Treatment with treprostinil neither reduced right ventricular hypertrophy nor improved right ventricular function. CONCLUSIONS: In the pulmonary trunk banding model of pressure overload-induced right ventricular hypertrophy and failure, moderate- and high-dose treatment with treprostinil did not improve right ventricular function neither in compensated nor in decompensated right heart failure.


Asunto(s)
Epoprostenol/análogos & derivados , Insuficiencia Cardíaca/tratamiento farmacológico , Hipertrofia Ventricular Derecha/tratamiento farmacológico , Función Ventricular Derecha/efectos de los fármacos , Animales , Antihipertensivos/administración & dosificación , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Epoprostenol/administración & dosificación , Insuficiencia Cardíaca/complicaciones , Insuficiencia Cardíaca/fisiopatología , Hipertrofia Ventricular Derecha/etiología , Hipertrofia Ventricular Derecha/fisiopatología , Infusiones Subcutáneas , Masculino , Ratas , Ratas Wistar
4.
Physiol Meas ; 36(5): 925-37, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25856199

RESUMEN

Right heart failure occurs in various heart and pulmonary vascular diseases and may be fatal. We aimed to identify limitations in non-invasive measurements of right ventricular stroke volume in an animal model of right ventricular failure. Data from previous studies randomising rats to pulmonary trunk banding (PTB, n = 33) causing pressure-overload right ventricular failure or sham operation (n = 16) was evaluated retrospectively. We measured right ventricular stroke volume by high frequency echocardiography and magnetic resonance imaging (MRI). We found correlation between right ventricular stroke volume measured by echocardiography and MRI in the sham animals (r = 0.677, p = 0.004) but not in the PTB group. Echocardiography overestimated the stroke volume compared to MRI in both groups. Intra- and inter-observer variation did not explain the difference. Technical, physiological and anatomical issues in the pulmonary artery might explain why echocardiography over-estimates stroke volume. Flow acceleration close to the pulmonary artery banding can cause uncertainties in the PTB model and might explain the lack of correlation. In conclusion, we found a correlation in right ventricular stroke volume measured by echocardiography versus MRI in the sham group but not the PTB group. Echocardiography overestimated right ventricular stroke volume compared to MRI.


Asunto(s)
Insuficiencia Cardíaca/fisiopatología , Pruebas de Función Cardíaca/métodos , Volumen Sistólico , Disfunción Ventricular Derecha/fisiopatología , Animales , Modelos Animales de Enfermedad , Ecocardiografía , Insuficiencia Cardíaca/diagnóstico , Imagen por Resonancia Magnética , Masculino , Ratas , Ratas Wistar
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA